Human Plasma Fatty Acid Oscillations

December 11, 2023 updated by: Carsten Skarke, MD, University of Pennsylvania

Exploratory Phase I Study to Define Plasma Fatty Acid Oscillations in Patients With Night Eating Syndrome Compared to Healthy Volunteers.

This study wishes to look at the 24-hour rhythm of certain fats in the blood stream. Recent studies in animals and healthy participants suggest that unusual eating habits may be connected to a change in the 24-hour rhythm of the blood fats the investigators wish to measure. The investigators will ask persons suffering from night eating syndrome, a condition where people eat additional meals throughout the night, to participate in this study. Healthy volunteers who are of the same age and gender, and have a comparable body-mass-index, a number calculated from a person's weight and height, will also be asked to participate.

The aim is to learn how the 24-hour rhythm of the blood fats the investigators measure differs between the persons experiencing the night eating episodes and persons who do not.

Study Overview

Status

Suspended

Detailed Description

A disease mechanism driving the clinical symptomology of the Night Eating Syndrome (NES) may be a metabolome, polyunsaturated fatty acids in particular, disrupted in its oscillations throughout the course of day and night. Blood and stool samples will be repeatedly taken during a 3-night/2-day protocol from NES patients and healthy controls with lights dimmed to 20 lux and time cues removed. Body core temperature and physical activity during the study will be monitored continuously.

Study Type

Observational

Enrollment (Estimated)

12

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with Night-Eating Syndrome: Participants have to meet both of the criteria for nocturnal ingestions and evening hyperphagia; eat 30% of their caloric intake after dinner with nocturnal wake ups to eat at a frequency of ≥ 5 times per week.

Matching healthy participants: Participantswill be matched to a patient with Night-Eating Syndrome by gender, age and BMI.

Description

Inclusion Criteria:

  • Volunteers must be in good health as based on medical history, physical examination, vital signs, and laboratory tests as deemed by PI, BMI of 27-32;
  • Volunteers are capable of giving informed consent;
  • 18-65 years of age;
  • Non-smoking; and
  • Non-pregnant, female subjects must consent to a urine pregnancy test.
  • Control subjects eat less than 25% of their caloric intake after dinner without nocturnal ingestions;
  • NES patients have to meet both of the criteria for nocturnal ingestions and evening hyperphagia; eat 30% of their caloric intake after dinner with nocturnal wake ups to eat at a frequency of ≥ 5 times per week

Exclusion Criteria:

  • Recent travel across time zones (within the past month);
  • Planned travel across time zones during the planned study activities;
  • Volunteers with irregular work hours, e.g. night shifts or swing shift schedule;
  • Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening;
  • Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject;
  • Diagnosis of severe depression, lifetime diagnosis of bipolar disorder or any psychotic disorder;
  • Prescription and non-prescription (OTC) medication; medication with psychotropics (including hypnotics);
  • Actively participating in a weight loss diet or program;
  • Diagnosed with a different eating disorder; and lack of awareness of the night eating episodes (to differentiate from nocturnal sleep-related eating disorder, in which nocturnal eating is accompanied by a lack of awareness at the time and amnesia for the behavior the following day.)

Exclusionary Medications and Substances

  • Subjects who have taken medications including antibiotics 2 weeks prior to the start of the study and throughout the study deemed by the investigator to interfere with the measurement of the study. Birth control pills are acceptable and will not be excluded;
  • Subjects who have taken aspirin or aspirin containing products for the 2 weeks prior to the start of the study and throughout the study;
  • Subjects who have taken acetaminophen, NSAIDS, COX-2 inhibitors (OTC or prescription) for 1 week prior to the start of the study and throughout the study;
  • Subjects who are currently consuming any type of tobacco product(s);
  • Use of recreational drugs within the last 6 months;
  • Subjects who consume high doses of antioxidant vitamins daily (vitamin C > 1000mg, Vitamin E > 400 IU, Beta Carotene > 1000IU, Vitamin A > 5000IU, Selenium > 200mcg, Folic Acid > 1mg) for the 2 weeks prior to the start of the study and throughout the study;
  • Subjects who consume caffeine or high fat food 72 hours prior to the start of each study visit;
  • Subjects need to abstain from alcohol consumption for 72 hours prior to the start of each study visit and throughout the active study.

Contraindications for the use of ingestible Temperature Sensors:

Screening for the contraindications listed below will occur during the physical and medical examination by a registered CTRC nurse or nurse practitioner:

  • In any patient whose body weight is less than eighty (80) pounds.
  • In the presence of any known or suspected obstructive disease of the gastrointestinal tract, including but not limited to diverticulitis and inflammatory bowel disease.
  • In any patient exhibiting or having a history of disorders or impairment of the gag reflex.
  • In any patient with previous gastrointestinal surgery.
  • In any patient having fenilization of the esophagus.
  • In any patient who might undergo Nuclear Magnetic Resonance (NMR) or MRI scanning during the period that the CorTemp® Disposable Temperature Sensor is within the body.
  • In any patient with hypo motility disorders of the gastrointestinal tract including but not limited to Ileus.
  • In any patient having a cardiac pacemaker or other implanted electro medical device.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Patients with Night-Eating Syndrome
Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
Matched Healthy Controls
Healthy volunteers; 18-65 years of age; eating <25% of their caloric intake after dinner; no nocturnal ingestions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma fatty acids
Time Frame: 64 hours
[% total fatty acid pool]
64 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood metabolite concentrations
Time Frame: 64 hours
[uM]
64 hours
Core body temperature
Time Frame: 64 hours
[degrees C]
64 hours
Bacterial taxa
Time Frame: 64 hours
The proportions of the genus "Firmicutes Streptococcus" differences between mornings (0, 24, 48 hours) versus evenings (12, 36 hours) in microbiota collected by oral swabs from the left and right cheek.
64 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kelly C Allison, PhD, University of Pennsylvania
  • Principal Investigator: Garret A FitzGerald, MD, University of Pennsylvania
  • Principal Investigator: Georgios Paschos, PhD, University of Pennsylvania

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2015

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

July 1, 2025

Study Registration Dates

First Submitted

July 2, 2015

First Submitted That Met QC Criteria

July 16, 2015

First Posted (Estimated)

July 20, 2015

Study Record Updates

Last Update Posted (Actual)

December 12, 2023

Last Update Submitted That Met QC Criteria

December 11, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

3
Subscribe